Acute myeloid leukemia.
Löwenberg
B
B
Department of Hematology, Erasmus University and University Hospital Rotterdam, The Netherlands.
Downing
J R
JR
Burnett
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins / Q000235:genetics; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D015479:Leukemia, Myelomonocytic, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D011379:Prognosis; D011518:Proto-Oncogene Proteins; D012008:Recurrence; D012074:Remission Induction; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000235:genetics; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D050676:Core Binding Factor Alpha 2 Subunit; D004268:DNA-Binding Proteins; D016298:Hematopoietic Cell Growth Factors; D011518:Proto-Oncogene Proteins; C493728:RUNX1 protein, human; D050656:Transcription Factor AP-2; D014157:Transcription Factors